查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827979

基因治疗市场按载体类型、治疗方法、目标基因组、递送方法、给药途径、患者类型、治疗领域和最终用户划分——全球预测 2025-2032

Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年基因治疗市场将成长至 759.2 亿美元，复合年增长率为 28.33%。

主要市场统计数据
基准年2024年 103.1亿美元
预计2025年 129.1亿美元
预测年份：2032年 759.2亿美元
复合年增长率（%） 28.33%

基因治疗从实验突破到相关人员综合开发和商业化的演化背景

基因治疗领域已从概念验证发展成为一个成熟的生态系统，临床疗效、监管清晰性和生产规模融合，最终形成一条商业性路径。载体工程和基因编辑平台的持续科学突破，加上对长期安全性的深入理解，扩大了可治疗疾病的范围，并提升了投资者和付款人的兴趣。因此，如今的策略重点不仅包括加速临床转化，还包括确保强大的供应链、标准化的分析方法以及永续的生产模式，以支持可重复的商业性上市。

全球监管机构日益注重协调产品特性、剂量滴定和长期追踪的指导，影响研究设计和核准策略。同时，付款人和卫生技术评估组织正在测试针对一次性和持久治疗的创新报销机制，这促使製造商制定更严格的真实世界证据产生计画。从单一专案的突破性进度到复杂的产品生命週期管理，需要涵盖研发、监管策略、製造和商业营运的综合能力。

在此背景下，决策者必须权衡技术选择（例如载体系统和递送方法）与临床目标、患者群体和物流限制。学术界、生物技术、合约研究公司和临床网路之间的多学科合作对于加快进度并确保安全和品质至关重要。本执行摘要的其余部分概述了结构性转变、政策影响、基于细分市场的洞察、区域动态以及实用建议，以帮助准备整个基因治疗价值链的策略性投资和营运。

识别同步的技术、製造、监管和付款人转变，重新定义基因治疗的发展重点和商业性可行性

基因治疗领域正被几个并行发生、相互促进的变革性转变所重塑。首先，平台多样化正在加速。载体技术和基因组修饰方法正变得更加专业化，使得治疗能够根据疾病生物学和患者群体进行客製化。这种技术多样化正在引发开发平臺的重新配置，早期专案现在强调载体最佳化、有效载荷设计和可製造性同步进行，而不是依次进行。

其次，製造和供应链的复杂性正在成为策略瓶颈和差异化因素。开发商正在投资模组化、灵活的製造能力，并深化与合约开发和製造机构的合作，以降低与病媒稀缺和批次差异相关的风险。除了营运重点之外，他们也越来越重视分析的稳健性和可比性研究，以确保批次一致性和法规的可接受性。

第三，付款方与医疗体系的对话正从假设性的可负担性讨论转向探索基于结果的合约、年金模式以及对真实世界证据的承诺的具体安排。这些资金筹措机制正在影响定价策略、终点选择和上市后证据项目。最后，监管的成熟度仍然是一个主要推动力，导致针对未满足需求高的适应症的指导意见不断更新，并加速了审批流程。这一转变需要跨科学、营运和商业学科的综合策略规划。

检验2025 年美国关税调整如何扩大供应风险、重塑筹资策略并加速基因治疗的区域製造业投资

美国于2025年实施的关税变化和贸易政策转变，为基因治疗生态系统中的机构带来了新的成本和物流考量。随着成本敏感型组件、试剂和专用设备跨境流通，这些政策调整提升了地理分布的供应链和製造布局的重要性。各公司正在重新调整筹资策略和库存政策，以便在不影响临床进度的情况下吸收或转嫁增加的进口关税。

管理阶层的即时因应措施包括尽可能优先考虑在地采购、加速替代供应商的资格审核，以及扩大区域製造能力以降低跨境风险。成本压力正促使一些开发商重新协商供应商合同，或与製造外包更紧密地合作，以找到互惠互利的效率。随着时间的推移，策略资本配置正在转向关键製造业务的在岸或近岸能力，尤其是载体製造和填充及表面处理工程，以保护专案免受关税波动的影响。

在专案层面，这些贸易动态也会影响全球临床实验设计和场地选择的决策。申办方必须在更广泛的病患可及性和监管多样性所带来的好处与临床实验物流日益增加的复杂性和成本之间取得平衡。总而言之，2025年的关税强化了全行业透过地理多元化、供应商冗余以及更紧密的商业策略和供应链计划整合来增强韧性的趋势。

揭示载体选择、治疗方式、目标基因组、递送方式、患者人口统计、治疗重点和最终用户角色如何影响策略发展选择

细分领域的动态揭示了不同的开发途径和营运要求，这些对临床策略和商业化准备有重大影响。同时，包括腺结合病毒载体、腺病毒载体、单纯疱疹病毒载体和逆转录病毒载体在内的病毒平台因其递送效率和组织趋向性而持续受到临床关注。这些固有的差异影响效力测试的开发、批次放行标准和低温运输物流的优先顺序。

治疗方法带来了监管和伦理方面的复杂性。同时，体细胞疗法（包括增强基因功能和抑制有害表达的方法）是近期临床应用的主要焦点。选择DNA或RNA修饰作为目标基因组，进一步影响治疗的持久性、脱靶风险和分析需求。 DNA编辑方法需要更全面的基因组表征，而RNA标靶策略则需要精确、瞬时的表达控制。

递送模式是另一个关键的细分轴心，体外方法需要整合细胞工程和製造能力，体内递送强调载体生物分布、免疫抗原性缓解和全身给药策略。肌肉注射、眼内注射和静脉注射等给药途径决定了临床试验设计、安全监测和治疗中心的程序基础设施。成人和儿童族群之间的患者类型分层决定了不同的终点、伦理考量和长期追踪的承诺。心血管应用，如冠状动脉疾病和心臟衰竭，需要与感染疾病目标（如B型肝炎和爱滋病毒）不同的终点和递送范例。单皮病，包括囊肿纤维化、血友病和镰状细胞性贫血，有独特的耐久性和校正基准。肿瘤学目标分为骨髓恶性肿瘤和固态肿瘤，需要不同的製造规模和组合策略。最终用户动态包括委外研发机构、医院/诊所、製药公司、生物技术公司和研究机构，每个组织的能力和采购模式各不相同，这些都会影响采用率和临床准备度。将这些细分洞察整合到专案规划中，可以实现有针对性的投资和风险调整后的时间表，使技术选择与临床和商业性需求保持一致。

解释美洲、欧洲、中东和非洲以及亚太地区的监管、临床和製造环境将如何影响战略进入和营运决策

区域动态对监管方法、临床试验生态系统、製造投资和伙伴关係模式有重大影响。在美洲，强大的创新生态系统和活跃的资本市场支持快速的临床应用和多个商业化上市，但该地区也面临着集中的製造需求，促使其在产能扩张和供应链韧性方面进行策略性投资。该地区的临床网络和付款人参与在证据生成和报销实验中发挥越来越重要的作用，塑造了新疗法的商业化策略。

欧洲、中东和非洲地区法律规范和医疗保健体系结构复杂多样，需要製定细緻入微的打入市场策略。欧洲集中的国家级监管路径促进了协调一致的科学讨论，但定价和准入方式必须因国家和地区而异。在中东和非洲市场，人们对产能建设、区域製造伙伴关係和临床试验参与的兴趣日益浓厚，这为患者提供了替代的准入途径，但基础设施和报销环境各不相同。随着申办方寻求在准入目标和营运可行性之间取得平衡，跨区域合作和技术转移正变得越来越普遍。

亚太地区的特点是患者群庞大、监管机构灵活，并在多个国家/地区对生物技术基础设施进行了大规模投资。多个市场正在积极制定奖励，以吸引临床试验和生产计划，而当地的生物製药生态系统也正在建立日益复杂的伙伴关係关係。不同地区的监管预期和报销准备情况各不相同，这要求相关人员采取分段式进入计划，并投资于本地证据生成和相关人员参与，以实现治疗效益。

重点介绍策略伙伴关係、製造专业化和产能投资如何重新定义主要企业的竞争定位和发展路径

基因治疗生态系统中的企业行为表明，它们重视策略联盟、可行的垂直整合以及在载体製造和分析开发等领域的有针对性的专业化。生物技术开发商越来越多地与合约开发和製造组织建立长期合作伙伴关係，以确保产能，并共同投资于製程改进，从而降低单位成本并提高产品一致性。同时，大型製药公司正在收购或授权平台技术，以扩展其治疗产品线，并将某些与临床开发和商业分销相关的能力引入公司内部。

对内部分析能力和品质系统的投资已成为竞争优势，使企业能够加快可比性检验，并支持监管机构加快监管路径。模组化製造解决方案和一次性技术也呈现出显着趋势，这些技术可部署于多个资产，以提高灵活性。策略性采购和供应商多元化已成为普遍现象，尤其是在稀有原料和专用耗材方面。企业认识到人力资本对于持续创新和卓越营运至关重要，因此优先发展载体生物学、製程开发和监管科学等先进技术领域的人才。

从企业发展角度来看，许可结构正在演变，涵盖里程碑和与结果挂钩的经济因素，这反映了付款人日益重要的作用以及奖励相关人员激励措施的必要性。这些发展凸显了自适应商业策略的重要性，该策略应在专案交付早期整合开发里程碑、生产准备情况和付款人参与计划。

优先整合製造、付款人参与、产品设计、区域营运和跨职能管治，将基因治疗创新转化为永续的市场成功

产业领导者必须专注于高影响力的优先事项，并采取果断行动，将科学潜力转化为持续的商业性成功。首先，无论是透过策略伙伴关係或选择性内部製造，投资于可扩展且灵活的製造能力，都可以降低专案风险，并使产品上市时间表更加可预测。此类投资应强调分析的严谨性、流程控制和供应链的多样性，以防止单点故障并促进监管互动。

其次，早期且持续的支付方参与对于制定临床试验终点、真实世界证据计划以及能够反映临床价值和机构可负担性的报销方案至关重要。设计整合临床结果和卫生经济指标的证据产生策略可以改善药物的可近性，并减少上市后摩擦。第三，优先考虑平衡生物效价和可生产性的技术和方案设计。这包括选择与现有生产能力和临床基地准备情况相符的载体、有效载荷形式和递送途径。

第四，采取区域营运策略，优化生产、临床试验和商业化活动的布局，最大限度地提高患者可及性，同时最大限度地降低关税风险和物流复杂性。最后，实施跨职能管治结构，协调研发、监管、生产和商业团队从专案启动到上市的各项工作，确保决策的一致性，加速价值实现。透过落实这些优先事项，产业领导者可以缩短产品到达患者手中的时间，并提高其基因治疗产品组合的整体永续性。

描述我们透明的三角调查方法，该方法结合专家访谈、科学文献、监管指导和供应链分析来产生可行的见解。

本执行摘要所依据的调查方法，结合了对公开科学文献、监管指南和行业披露资讯的结构化综合，以及对研发、生产、监管和商业战略领域专家的访谈，并得出了定性见解。主要资讯包括与开发人员、第三方製造商、临床研究人员和付款人顾问的对话，这些对话揭示了公开声明中并不常见的实际限制和策略应对措施。二次研究着重于同侪审查研究、监管沟通和技术白皮书，以支持机制和技术主张。

本研究运用资料三角测量法来协调不同的观点并检验主题结论，并强调可重复性和方法透明度。在讨论贸易政策影响或区域动态时，三角测量法也纳入了公共声明和对产业供应链的评论。调查方法认识到快速发展的科学数据固有的局限性以及许多商业性安排的专有性。因此，我们将质性研究结果与技术文献结合，以建构稳健的、基于背景的洞察，而非进行量化预测。

在专家咨询中，我们秉持研究诚信和保密的道德标准，并透过揭露和分发资讯来源来管理潜在的利益衝突。研究设计强调为决策者提供切实可行的见解和策略相关性，帮助他们在基因治疗开发和商业化方面考虑投资、合作和营运承诺。

摘要科学进步、营运准备以及付款人和监管期望将如何融合，以确定哪些基因治疗计画将实现持续的临床和商业性影响

基因治疗正处于科学成熟度与商业性复杂性交彙的曲折点。载体工程、基因组修饰技术和临床经验的进步正在拓展治疗的可能性，但其成功越来越依赖卓越的运营，包括生产、分析和供应链管理。监管机构和支付方正在推动研发机构将临床设计和证据计划与长期安全性和价值展示的要求相结合。这种融合凸显了综合策略规划的重要性，该规划应能预测生产限制、区域监管差异以及支付方谈判。

采用整体方法，将技术选择、患者群体策略、临床实验准备和报销计划并行不悖的开发组织，将更有能力将科学前景转化为持续的临床和商业性成果。建构富有弹性和灵活性的营运体系、投资关键分析能力以及在整个生态系统中建立合作伙伴关係关係，是应对技术和政策不确定性的切实可行的方法。随着该领域的不断发展，成功将青睐那些能够平衡科学抱负与务实、以实施为导向的策略，并优先考虑患者可及性和长期安全监测的机构。

本摘要提炼了当前的结构驱动因素和操作要求，为高管指南提供信息，并指导将基因治疗从实验成功推进到持续临床影响所需的优先投资。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • CRISPR碱基编辑技术的进步使得遗传疾病中的单碱基精确校正成为可能
  • 脂质奈米颗粒递送系统的出现提高了标靶效率和安全性
  • 透过新型衣壳工程降低免疫反应，AAV载体疗法在临床上获得成功
  • 将人工智慧驱动的生物资讯整合到基因治疗设计中，以优化载体特异性和效力
  • 全球主要市场体内基因编辑疗法监管核准途径的演变
  • 利用新型抗原标靶策略开发体外CAR-T基因修饰细胞治疗固态肿瘤
  • 采用电穿孔和奈米颗粒复合物等非病毒递送方法来降低製造成本
  • 个人化基因治疗的成长由先进的基因组分析和患者特定的载体客製化推动
  • 生技公司与大型製药公司建立策略联盟，加速后期临床管线开发

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章 基因治疗市场（依载体型）

  • 非病毒载体
    • 脂质体转染
    • 质体DNA
  • 病毒载体
    • 腺结合病毒（AAV）载体
    • 腺病毒载体
    • 单纯疱疹病毒（HSV）载体
    • 逆转录病毒载体

第九章 基因治疗市场（依治疗方法类型）

  • 生殖细胞治疗
  • 体细胞疗法
    • 基因增强疗法
    • 基因抑制疗法

第 10 章 基因治疗市场（按目标基因组）

  • DNA修饰
  • RNA修饰

第 11 章 基因治疗市场（依交付方式）

  • 体外
  • 体内

第十二章 基因治疗市场（依给药途径）

  • 肌肉注射
  • 眼
  • 静脉

第十三章 基因治疗市场（依病患类型）

  • 成年患者
  • 儿科患者

第十四章 基因治疗市场（依治疗领域）

  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 单基因疾病
    • 囊肿纤维化
    • 血友病
    • 镰状细胞性贫血
  • 肿瘤疾病
    • 造血系统恶性肿瘤
    • 固态肿瘤

第十五章 基因治疗市场（依最终用户）

  • CRO（委外研发机构）
  • 医院和诊所
  • 製药和生物技术公司
  • 研究所

第十六章 基因治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 基因治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 各国基因治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争态势

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics PLC
    • Adverum Biotechnologies, Inc.
    • AGC Biologics
    • Alnylam Pharmaceuticals, Inc.
    • American Gene Technologies Inc.
    • Amgen Inc.
    • AnGes, Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.
    • bluebird bio, Inc.
    • Cellectis SA
    • CRISPR Therapeutics AG
    • Danaher Corporation
    • Editas Medicine, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Intellia Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Mustang Bio, Inc.
    • Novartis AG
    • Orchard Therapeutics PLC
    • Poseida Therapeutics, Inc.
    • Sangamo Therapeutics, Inc.
    • Sarepta Therapeutics, Inc.
    • Sibiono GeneTech Co. Ltd.
    • Syncona Limited
    • ViGeneron GmbH
    • Voyager Therapeutics Inc.
Product Code: MRR-437517DB6C62

The Gene Therapy Market is projected to grow by USD 75.92 billion at a CAGR of 28.33% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.31 billion
Estimated Year [2025] USD 12.91 billion
Forecast Year [2032] USD 75.92 billion
CAGR (%) 28.33%

Contextualizing the evolution of gene therapy from experimental breakthroughs to integrated development and commercialization imperatives across stakeholders

The gene therapy field has moved from proof-of-concept demonstrations to a maturing ecosystem where clinical efficacy, regulatory clarity, and manufacturing scale converge to shape commercial pathways. Continued scientific breakthroughs in vector engineering and editing platforms, coupled with deeper understanding of long-term safety profiles, have expanded the set of treatable conditions and broadened investor and payer interest. As a result, strategic priorities now include not only accelerating clinical translation but also ensuring robust supply chains, standardized analytical methods, and sustainable manufacturing models that can support repeatable commercial launches.

Regulatory agencies globally are increasingly focused on harmonizing guidance around product characterization, potency assays, and long-term follow-up, which is influencing trial design and approval strategies. Concurrently, payers and health technology assessment bodies are testing innovative reimbursement mechanisms for one-time or durable therapies, prompting manufacturers to build more rigorous real-world evidence generation plans. This transition from single-asset breakthrough narratives to complex product life-cycle management demands integrated capabilities across R&D, regulatory strategy, manufacturing, and commercial operations.

In this context, decision makers must weigh technological choices-such as vector systems and delivery modes-against clinical objectives, patient populations, and logistical constraints. Interdisciplinary collaboration across academia, biotech, contract developers, and clinical networks is critical to shorten timelines while preserving safety and quality. The remainder of this executive summary synthesizes the structural shifts, policy impacts, segmentation-driven insights, regional dynamics, and practical recommendations to inform strategic investments and operational readiness across the gene therapy value chain.

Identifying concurrent technological, manufacturing, regulatory, and payer shifts that are redefining development priorities and commercial viability in gene therapy

The landscape for gene therapy is being reshaped by several transformative shifts that operate in parallel and reinforce one another. First, platform diversification has accelerated; vector technologies and genome modulation approaches have become more specialized, enabling therapies that are increasingly tailored to disease biology and patient subpopulations. This technical diversification has induced a reconfiguration of R&D pipelines, with early-stage programs emphasizing vector optimization, payload design, and manufacturability concurrently rather than sequentially.

Second, manufacturing and supply chain sophistication are emerging as strategic bottlenecks and differentiators. Developers are investing in modular, flexible manufacturing capacity and deeper engagements with contract development and manufacturing organizations to mitigate risks associated with vector scarcity and lot variability. This operational focus is complemented by a growing emphasis on analytical robustness and comparability studies to ensure batch consistency and regulatory acceptance.

Third, payer and health system conversations have moved from hypothetical affordability debates to concrete arrangements exploring outcomes-based contracts, annuity models, and real-world evidence commitments. These financing mechanisms are influencing pricing strategy, trial endpoint selection, and post-launch evidence programs. Lastly, regulatory maturation continues to be a major force, with agencies issuing iterative guidance and adopting expedited pathways for high-unmet-need indications, while also tightening expectations around long-term safety monitoring and product characterization. Together, these shifts demand integrated strategic planning that spans scientific, operational, and commercial disciplines.

Examining how United States tariff adjustments in 2025 amplified supply risk, reshaped sourcing strategies, and accelerated regional manufacturing investments across gene therapy

Tariff changes and trade policy shifts implemented in 2025 in the United States introduced new cost and logistical considerations for organizations operating in the gene therapy ecosystem. These policy adjustments have magnified the importance of geographically diversified supply chains and manufacturing footprints, as components, reagents, and specialized equipment traverse international borders with greater cost sensitivity. Companies are recalibrating sourcing strategies and inventory policies to absorb or pass through incremental import duties without compromising clinical timelines.

The immediate operational response has included prioritizing local content where feasible, accelerating qualification of alternative suppliers, and expanding regional manufacturing capacity to reduce cross-border exposure. For some developers, the added cost pressure has prompted renegotiation of vendor contracts and closer collaboration with contract manufacturers to identify mutual efficiencies. Over time, strategic capital allocation is shifting toward on-shore or near-shore capabilities for critical production steps, particularly vector manufacture and fill/finish operations, to insulate programs from tariff volatility.

At a program level, these trade dynamics also influence decision making around global trial design and site selection. Sponsors must balance the benefits of broader patient access and regulatory diversification against the added complexity and cost of cross-border logistics. In sum, tariff measures implemented in 2025 have reinforced a broader industry trend toward resilience through geographic diversification, supplier redundancy, and closer integration between commercial strategy and supply chain planning.

Articulating how vector selection, treatment modality, target genome, delivery mode, patient demographics, therapeutic focus, and end-user roles collectively shape strategic development choices

Segment-level dynamics reveal heterogeneous development pathways and operational requirements that materially affect clinical strategies and commercialization readiness. When analyzed by vector type, distinctions between non-viral and viral platforms are notable: non-viral approaches such as lipofection and plasmid DNA frequently offer advantages in dose control and manufacturing scalability, while viral platforms including adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors continue to drive sustained clinical interest because of their transduction efficiency and tissue tropism. These intrinsic differences influence priorities in potency assay development, lot release criteria, and cold-chain logistics.

Treatment modality introduces regulatory and ethical complexity. Germline interventions remain subject to heightened ethical scrutiny and constrained pathways, whereas somatic cell therapies-comprising approaches that augment gene function and those that suppress deleterious expression-are the primary focus of near-term clinical translation. Choices between DNA modification and RNA modification as the target genome further affect therapeutic durability, off-target risk profiles, and analytical needs, with DNA editing approaches necessitating more extensive genomic characterization and RNA-targeting strategies demanding precise transient expression control.

Delivery mode is another pivotal segmentation axis, where ex vivo approaches require integrated cellular manipulation and manufacturing capabilities, while in vivo delivery places premium emphasis on vector biodistribution, immunogenicity mitigation, and systemic dosing strategies. Route of administration across intramuscular, intraocular, and intravenous pathways determines clinical trial design, safety monitoring, and procedural infrastructure at treatment centers. Patient type stratification between adult and pediatric populations drives differential endpoints, ethical considerations, and long-term follow-up commitments. Therapeutic area segmentation spanning cardiovascular, infectious, monogenic, and oncological disorders imposes diverse clinical evidence expectations; cardiovascular applications such as coronary artery disease and heart failure demand different endpoints and delivery paradigms than infectious disease targets like hepatitis B and HIV, while monogenic disorders including cystic fibrosis, hemophilia, and sickle cell anemia have unique durability and correctional benchmarks and oncology targets split between hematological malignancies and solid tumors require distinct manufacturing scales and combination strategies. End-user dynamics involve contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, each bringing different capabilities and procurement models that affect adoption velocity and clinical readiness. Integrating these segmentation insights into program planning enables targeted investments and risk-adjusted timelines that align technological choice with clinical and commercial imperatives.

Explaining how regional regulatory, clinical, and manufacturing environments in the Americas, Europe Middle East & Africa, and Asia-Pacific inform strategic entry and operational decisions

Regional dynamics exert profound influence over regulatory approaches, clinical trial ecosystems, manufacturing investments, and partnership models. In the Americas, a robust innovation ecosystem and active capital markets have supported rapid clinical translation and multiple commercial launches, but this region also faces concentrated manufacturing demand that drives strategic investments in capacity expansion and supply chain resilience. Clinical networks and payer engagement in this region are increasingly central to evidence generation and reimbursement experimentation, shaping the commercialization playbook for novel therapies.

The Europe, Middle East & Africa region presents a mosaic of regulatory frameworks and health system structures, which requires nuanced market entry strategies. European centralized and national regulatory pathways encourage harmonized scientific discussion but necessitate tailored pricing and access approaches across jurisdictions. Middle Eastern and African markets show growing interest in capacity building, regional manufacturing partnerships, and clinical trial participation, offering alternative patient access routes but with variable infrastructure and reimbursement environments. Cross-region collaboration and technology transfer are becoming more common as sponsors seek to balance access goals with operational feasibility.

Asia-Pacific is characterized by a combination of large patient pools, emerging regulatory agility, and significant investments in biotechnology infrastructure across multiple countries. Several markets are proactively creating incentives to attract clinical trials and manufacturing projects, and local biopharma ecosystems are producing increasingly sophisticated partnerships. Differences in regulatory expectations and reimbursement readiness across the region require sponsors to adopt segmented entry plans and to invest in local evidence generation and stakeholder engagement to realize therapeutic impact.

Highlighting how strategic partnerships, manufacturing specialization, and capability investments are redefining competitive positioning and development pathways among leading companies

Company behaviors across the gene therapy ecosystem illustrate an emphasis on strategic partnering, vertical integration where feasible, and specialization that targets bottlenecks such as vector manufacture and analytical development. Biotech developers are increasingly forming long-term alliances with contract developers and manufacturing organizations to secure capacity and to co-invest in process improvements that reduce unit cost and enhance product consistency. Parallel to this, larger pharmaceutical companies are acquiring or licensing platform technologies to broaden therapeutic pipelines and to internalize specific capabilities around clinical development and commercial distribution.

Investment in in-house analytical capabilities and quality systems has become a competitive differentiator, enabling companies to accelerate comparability exercises and support accelerated regulatory pathways. There is also a notable trend toward modular manufacturing solutions and single-use technologies that can be deployed across multiple assets to improve flexibility. Strategic sourcing and supplier diversification are common, particularly for rare raw materials and specialized consumables. Companies are prioritizing talent development in highly technical areas such as vector biology, process development, and regulatory science, recognizing that human capital is critical to sustaining innovation and operational excellence.

From a corporate development perspective, licensing structures are evolving to include milestone and outcomes-linked economics, reflecting the increasing role of payers and the need to align incentives across stakeholders. These developments underscore the importance of adaptive commercial strategies that integrate development milestones, manufacturing readiness, and payer engagement plans early in program realization.

Prioritize integrated manufacturing, payer engagement, product design, regional operations, and cross-functional governance to convert gene therapy innovation into sustainable market success

Industry leaders should act decisively to translate scientific potential into durable commercial success by focusing on a handful of high-impact priorities. First, investment in scalable and flexible manufacturing capacity-whether through strategic partnerships or selective in-house build-will reduce program risk and enable more predictable launch timelines. Such investments should emphasize analytical rigor, process control, and supply chain diversity to guard against single-point failures and to facilitate regulatory interactions.

Second, early and ongoing payer engagement is essential to shape trial endpoints, real-world evidence plans, and reimbursement approaches that reflect both clinical value and system affordability. Designing evidence generation strategies that integrate clinical outcomes with health economic measures will improve access prospects and reduce post-launch friction. Third, prioritize technologies and program designs that balance biological potency with manufacturability; this includes choosing vectors, payload formats, and delivery routes that align with available production capabilities and clinical site readiness.

Fourth, adopt regionalized operational strategies that optimize the placement of manufacturing, clinical trials, and commercialization activities to minimize tariff exposure and logistics complexity while maximizing patient access. Finally, embed cross-functional governance structures that align R&D, regulatory, manufacturing, and commercial teams from program inception through launch to ensure coherent decision making and to accelerate value realization. By operationalizing these priorities, industry leaders can reduce time-to-patient and improve the overall sustainability of gene therapy portfolios.

Describing a transparent, triangulated research methodology that integrates expert interviews, scientific literature, regulatory guidance, and supply-chain analysis to generate actionable insights

The research approach underpinning this executive summary combined a structured synthesis of publicly available scientific literature, regulatory guidance, and industry disclosures with qualitative insights from interviews with subject matter experts across development, manufacturing, regulation, and commercial strategy. Primary inputs included conversations with developers, third-party manufacturers, clinical investigators, and payer advisors to surface practical constraints and strategic responses that are not always evident in formal publications. Secondary research emphasized peer-reviewed studies, regulatory agency communications, and technical white papers to corroborate mechanistic and technological assertions.

Data triangulation was applied to reconcile diverse perspectives and to validate thematic conclusions, with a focus on reproducibility and methodological transparency. Where trade policy impacts and regional dynamics were discussed, triangulation included public policy announcements and industry supply-chain commentaries. The methodology acknowledges limitations associated with rapidly evolving scientific data and the proprietary nature of many commercial arrangements; therefore, qualitative findings were blended with technical literature to build robust, contextualized insights rather than to produce quantitative projections.

Ethical standards for research integrity and confidentiality were maintained during expert consultations, and potential conflicts of interest were managed through disclosure and source diversification. The research design emphasizes actionable insight generation and strategic relevance for decision makers considering investment, partnership, or operational commitments in gene therapy development and commercialization.

Summarizing how scientific advances, operational readiness, and payer and regulatory expectations converge to determine which gene therapy programs achieve sustained clinical and commercial impact

Gene therapy is at an inflection point where scientific maturity and commercial complexity intersect. Advances in vector engineering, genome modulation technologies, and clinical experience have expanded the therapeutic horizon, but success increasingly depends on operational excellence across manufacturing, analytics, and supply chain management. Regulatory agencies and payers are refining expectations, driving developers to align clinical design and evidence plans with long-term safety and value demonstration imperatives. This confluence elevates the importance of integrated strategic planning that anticipates manufacturing constraints, regional regulatory variability, and payer negotiations.

Organizations that adopt a holistic approach-where technology selection, patient population strategy, site readiness, and reimbursement planning are developed in parallel-will be better positioned to translate scientific promise into sustained clinical and commercial outcomes. Building resilient and flexible operations, investing in critical analytical capabilities, and fostering collaborative partnerships across the ecosystem are practical levers to manage technical and policy uncertainties. As the field continues to evolve, success will favor those who balance scientific ambition with pragmatic, execution-oriented strategies that prioritize patient access and long-term safety monitoring.

This summary distills current structural drivers and operational imperatives intended to inform executive decision making and to guide prioritized investments necessary for advancing gene therapies from experimental success to durable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in CRISPR base editing enabling precise single-base corrections in inherited disorders
  • 5.2. Emergence of lipid nanoparticle delivery systems improving gene therapy targeting efficiency and safety
  • 5.3. Clinical success of AAV vector therapies reducing immune response through novel capsid engineering
  • 5.4. Integration of AI-driven bioinformatics in gene therapy design to optimize vector specificity and potency
  • 5.5. Regulatory approval pathways evolving for in vivo gene editing therapies across major global markets
  • 5.6. Expansion of ex vivo CAR T gene-modified cell therapies into solid tumors with novel target antigen strategies
  • 5.7. Adoption of non-viral delivery methods such as electroporation and nanoparticle conjugates to reduce manufacturing costs
  • 5.8. Growth of personalized gene therapies driven by advanced genomic profiling and patient-specific vector customization
  • 5.9. Strategic partnerships between biotech and big pharma accelerating late-stage gene therapy clinical pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Therapy Market, by Vector Type

  • 8.1. Non-Viral Vectors
    • 8.1.1. Lipofection
    • 8.1.2. Plasmid DNA
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated Virus (AAV) Vectors
    • 8.2.2. Adenovirus Vectors
    • 8.2.3. Herpes Simplex Virus (HSV) Vectors
    • 8.2.4. Retrovirus Vectors

9. Gene Therapy Market, by Treatment Modality

  • 9.1. Germline Therapy
  • 9.2. Somatic Cell Therapy
    • 9.2.1. Gene Augmentation Therapy
    • 9.2.2. Gene Suppression Therapy

10. Gene Therapy Market, by Target Genome

  • 10.1. DNA Modification
  • 10.2. RNA Modification

11. Gene Therapy Market, by Delivery Mode

  • 11.1. Ex Vivo
  • 11.2. In Vivo

12. Gene Therapy Market, by Route of Administration

  • 12.1. Intramuscular
  • 12.2. Intraocular
  • 12.3. Intravenous

13. Gene Therapy Market, by Patient Type

  • 13.1. Adult Patients
  • 13.2. Pediatric Patients

14. Gene Therapy Market, by Therapeutic Area

  • 14.1. Cardiovascular Diseases
    • 14.1.1. Coronary Artery Disease
    • 14.1.2. Heart Failure
  • 14.2. Infectious Diseases
    • 14.2.1. Hepatitis B
    • 14.2.2. HIV
  • 14.3. Monogenic Disorders
    • 14.3.1. Cystic Fibrosis
    • 14.3.2. Hemophilia
    • 14.3.3. Sickle Cell Anemia
  • 14.4. Oncological Disorders
    • 14.4.1. Hematological Malignancies
    • 14.4.2. Solid Tumors

15. Gene Therapy Market, by End-User

  • 15.1. Contract Research Organizations
  • 15.2. Hospitals & Clinics
  • 15.3. Pharmaceutical & Biotech Companies
  • 15.4. Research Institutes

16. Gene Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Gene Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Gene Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Abeona Therapeutics Inc.
    • 19.3.2. Adaptimmune Therapeutics PLC
    • 19.3.3. Adverum Biotechnologies, Inc.
    • 19.3.4. AGC Biologics
    • 19.3.5. Alnylam Pharmaceuticals, Inc.
    • 19.3.6. American Gene Technologies Inc.
    • 19.3.7. Amgen Inc.
    • 19.3.8. AnGes, Inc.
    • 19.3.9. Astellas Pharma Inc.
    • 19.3.10. Biogen Inc.
    • 19.3.11. bluebird bio, Inc.
    • 19.3.12. Cellectis S.A.
    • 19.3.13. CRISPR Therapeutics AG
    • 19.3.14. Danaher Corporation
    • 19.3.15. Editas Medicine, Inc.
    • 19.3.16. F. Hoffmann-La Roche Ltd.
    • 19.3.17. Gilead Sciences, Inc.
    • 19.3.18. Intellia Therapeutics
    • 19.3.19. Ionis Pharmaceuticals, Inc.
    • 19.3.20. Johnson & Johnson
    • 19.3.21. Merck KGaA
    • 19.3.22. Mustang Bio, Inc.
    • 19.3.23. Novartis AG
    • 19.3.24. Orchard Therapeutics PLC
    • 19.3.25. Poseida Therapeutics, Inc.
    • 19.3.26. Sangamo Therapeutics, Inc.
    • 19.3.27. Sarepta Therapeutics, Inc.
    • 19.3.28. Sibiono GeneTech Co. Ltd.
    • 19.3.29. Syncona Limited
    • 19.3.30. ViGeneron GmbH
    • 19.3.31. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2